TGFB2 and systemic sclerosis: Furthermore, TGFB2 expression demonstrated the ability to discriminate between patients with SSc-ILD and those with SSc-nonILD, acting as an early diagnostic biomarker of ILD in SSc (AUC: 0.7518, p = 0.0040, Figure 3B, Table S1).